Haleon plc
In the published model solve dated 2026-Q2, anchored at $9.95, Haleon plc (HLN) is priced for -2.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Haleon is a pure-play consumer-health company built on category-leading brands across Oral Health, vitamins, Pain Relief, Respiratory, and Digestive Health, with Sensodyne and parodontax delivering double-digit growth in the most recent quarter on innovation and geographic expansion. [Source: Q1 2026 trading statement] • The biggest near-term risk is volume: organic revenue grew just 2.2% in Q1 2026 with price up 2.4% and volume down 0.2%, meaning the top line is being carried by pricing rathe
Is HLN overvalued? See what's priced in →
612 institutional managers reported holding HLN in 13F filings for the quarter ended 2026-03-31. Together they hold about 6% of the company; the top 10 hold 4%. 76 opened new positions that quarter. Held by Dodge & Cox, FMR (Fidelity), Morgan Stanley, among others. On the short side, 15.0M shares were sold short as of the 2026-06-15 count, about 0.2% of shares outstanding (1.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HLN has cut its share count 2.7% over the past five years. It pays a dividend, and has paid one every year in our records (6 and counting). Cash returned over the past three years: $2.48B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.